Yannis K. Valtis
A5088473676- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Global Cancer Incidence and Screening
- Chronic Lymphocytic Leukemia Research
- Adolescent and Pediatric Healthcare
- Economic and Financial Impacts of Cancer
- Traumatic Brain Injury and Neurovascular Disturbances
- Viral Infectious Diseases and Gene Expression in Insects
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Bone and Joint Diseases
- Innovations in Medical Education
- Global Health and Surgery
- Methemoglobinemia and Tumor Lysis Syndrome
- Biosimilars and Bioanalytical Methods
- Advanced MRI Techniques and Applications
- Virus-based gene therapy research
- Adenosine and Purinergic Signaling
- Hematopoietic Stem Cell Transplantation
- Primary Care and Health Outcomes
- Advancements in Semiconductor Devices and Circuit Design
- Cerebrospinal fluid and hydrocephalus
- Health Sciences Research and Education
Memorial Sloan Kettering Cancer Center
2022-2025
Brigham and Women's Hospital
2019-2023
Kettering University
2022-2023
Harvard University
2016-2022
Boston Children's Hospital
2022
Massachusetts General Hospital
2017-2018
Harvard Stem Cell Institute
2017
Harvard Global Health Institute
2016
PURPOSE We designed a CD19-targeted chimeric antigen receptor (CAR) comprising calibrated signaling module, termed 1XX, that differs from of conventional CD28/CD3ζ and 4-1BB/CD3ζ CARs. Preclinical data demonstrated 1XX CARs generated potent effector function without undermining T-cell persistence. hypothesized CAR T cells may be effective at low doses elicit minimal toxicities. METHODS In this first-in-human, phase I, dose escalation expansion clinical trial, patients with relapsed or...
Diabetes mellitus is associated with poor outcomes in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Diabetic ketoacidosis (DKA) has also been reported to occur this virus. A cluster of cases euglycemic DKA (euDKA) was identified patients type diabetes using sodium-glucose cotransporter-2 inhibitors (SGLT2is) who developed SARS-CoV-2 infection.The were by the authors while providing clinical care, and details collected.Five euDKA, presenting glucose levels <300...
Nelarabine, an antimetabolite prodrug, is approved as monotherapy for children and adults with relapsed refractory T-cell acute lymphoblastic leukemia lymphoma (R/R T-ALL/LBL), although it often used in combination regimens. We sought to understand differences efficacy toxicity when nelarabine administered alone or combination. retrospectively analyzed 44 consecutive patients R/R T-ALL/LBL; 29 of whom were treated therapy, most cyclophosphamide etoposide (23, 79%) 15 monotherapy. The median...
Adolescent and young adults (AYAs) with acute lymphoblastic leukemia (ALL) treated asparaginase-containing pediatric regimens are commonly overweight or obese. We studied the association of body mass index (BMI) on outcomes 388 AYAs aged 15 to 50 years Dana-Farber Cancer Institute (DFCI) consortium (2008-2021). BMI was normal in 207 (53.3%) overweight/obese 181 (46.7%). Patients who were obese experienced higher nonrelapse mortality (NRM; 4-year, 11.7% vs 2.8%, P = .006), worse event-free...
Nervous system injury is a frequent result of cancer therapy involving cranial irradiation, leaving patients with marked memory and other neurobehavioral disabilities. Here, we report an unanticipated link between bone marrow brain in the setting radiation injury. Specifically, demonstrate that marrow-derived monocytes macrophages are essential for structural functional repair mechanisms, including regeneration cerebral white matter improvement neurocognitive function. Using...
On the basis of results ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes patients treated brexu-cel as standard therapy.
This cohort study examines barriers to access of CAR T-cell therapy among patients with hematologic cancer referred for this treatment.
The utility of a mid-cycle bone marrow biopsy (BMB) for early assessment response in patients with acute myeloid leukemia (AML) after intensive chemotherapy (IC) induction is contested. Even when challenged, there little consideration as to the possibility different dynamics among genetically defined subgroups. Clinical observations led hypothesis that AML and mutations IDH2-R172 (R172-m) exhibit particularly slow blast reduction following IC induction. purpose this study was analyze...
Relapsed/Refractory (r/r) B-cell acute lymphoblastic leukemia patients with central nervous system involvement (CNS B-ALL) have poor outcomes and were frequently excluded from CD19-targeting chimeric antigen receptor T-cell (CAR T-cell) clinical trials. The efficacy safety of brexucabtagene autoleucel (brexu-cel) in adults r/r B-ALL was established by the ZUMA-3 trial, which advanced or symptomatic CNS involvement. In this retrospective multicenter analysis, we investigated brexu-cel...
The rapidly changing landscape of medical knowledge and guidelines requires health professionals to have immediate access current, reliable clinical resources. Access evidence is instrumental in reducing diagnostic errors generating better outcomes. UpToDate, a leading evidence-based resource used extensively the USA other regions world has been linked lower mortality length stay US hospitals. In 2009, Global Health Delivery Project collaborated with UpToDate provide free subscriptions...
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis 189 patients relapsed/refractory ALL treated brexu-cel. Over half the received InO before brexu-cel (InO exposed). InO-exposed were more heavily pretreated (P = .02) and frequently had active marrow disease apheresis .03). Response rate toxicity profile after comparable...
Abstract Venetoclax is a B-cell lymphoma 2 inhibitor used in chronic lymphocytic leukemia (CLL), which can cause tumor lysis syndrome (TLS). We aimed to determine the incidence of, and risk factors for, TLS among patients with CLL/small who received treatment venetoclax at our institution from 1 January 2016 31 December 2020. included 616 escalations 136 CLL. Overall, 74 (54%) underwent escalation exclusively outpatient, 35 (26%) had least planned hospitalization, 27 (20%) were escalated...
The combination of a hypomethylating agent (HMA) and venetoclax (VEN) is approved for adults older than 75-years-old with newly diagnosed acute myeloid leukemia (AML) as well those ineligible intensive chemotherapy (IC). HMA/VEN increasingly substituted IC in AML younger 75, particularly adverse cytogenetic molecular features. When patients fail to respond or relapse after HMA/VEN, the utility salvage largely unknown. We performed retrospective single-institution study identified 46 who...
Abstract Asparaginase (ASP)-containing regimens for acute lymphoblastic leukemia (ALL) are associated with venous thromboembolism (VTE). We evaluated the prevalence, risk factors, role of prophylaxis and clinical impact VTE among adolescents young adult (AYA) patients (15–50 years) treated on Dana-Farber Cancer Institute (DFCI) ALL protocols. The 1- 2-year cumulative incidence were 31.9% (95% CI: 27.0%, 36.9%) 33.5% 28.5%, 38.5%) respectively, most events occurring during ASP-based...
Immune effector cell-associated hematotoxicity (ICAHT) is a major B-cell targeted chimeric antigen receptor (CAR) T-cell related toxicity. While ICAHT incidence and severity documented in large lymphoma (LBCL), mantle cell (MCL), multiple myeloma (MM), has not been described acute lymphoblastic leukemia (B-ALL). Similarly, the CAR-HEMATOTOX (CAR-HT) model, designed to predict severe prolonged neutropenia (&gt;14 days of ANC &lt;500/µl), validated LBCL, MCL, MM, but B-ALL. As B-ALL...
Adolescent and young adult patients with acute lymphoblastic leukemia (ALL) have superior outcomes when treated on pediatric regimens. Pediatric ALL regimens rely heavily corticosteroids asparaginase are known to increase the risk of osteonecrosis (ON) fractures in children, particularly adolescents. Orthopedic toxicity among adults pediatric-inspired is not well described. Here, we report symptomatic orthopedic toxicities aged 15 50 years sequential Dana-Farber Cancer Institute Consortium...